Compare Vaxcyte Inc. Common Stock (PCVX) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Global X Defense Tech ETF — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Global X Defense Tech ETF trades at $59.55 (market cap $6.34B). The key difference: Vaxcyte Inc. Common Stock is the larger of the two by market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Global X Defense Tech ETF for 45 Days on average.
| PCVX | SHLD | |
|---|---|---|
Market Cap | $10.51B | $6.34B |
Volume | 2,644,694 | 1,202,620 |
Sector | Health | Sector/Thematic |
52-Week High | $73.82 | $78.02 |
52-Week Low | $40.32 | $58.20 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $9.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SHLD (Global X Defense Tech ETF) trades at $59.34, down 0.82% with a bearish technical outlook as moving averages signal strong selling pressure. The ETF focuses on defense technology and cybersecurity with global diversification beyond U.S. names. Recent institutional buying includes Focus Financial Network increasing its stake by 55.4% in Q2 2026 (SEC filing, August 2026) and Balefire LLC's new $1.12 million position.
Geopolitical tensions and rising global defense budgets support long-term growth potential, though the ETF faces competition from broader aerospace funds and sensitivity to defense policy changes. The current technical weakness near support at $58-59 presents a potential entry point for investors bullish on defense tech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
